The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Novartis (United States) · Novartis (Switzerland) · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
591
total citations
- FWCI
- 33.77
- Percentile
- 100%
- References
- 20
Citations per year
Authors
28- AAAndrew A. WylieCorresponding
Novartis (United States)
- JSJoseph Schoepfer
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- WJWolfgang Jahnke
Novartis Institutes for BioMedical Research, Novartis (Switzerland)
- SWSandra W. Cowan‐Jacob
Novartis Institutes for BioMedical Research, Novartis (Switzerland)
- ALAlice Loo
Novartis (United States)
Topics & keywords
Topics
Keywords
- Imatinib
- Allosteric regulation
- ABL
- Myeloid leukemia
- Cancer research
- Imatinib mesylate
- Pharmacology
- Medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.